- The financing was co-led by LAV and Foresite Capital with participation from existing investors including Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and OrbiMed.
- The company has raised $134 million to date after incubation by OrbiMed and other healthcare specialist investors.
- Achievements will support the advancement of the oral peptide pipeline through clinical proof of concept
Shanghai and Dialston, Pa., March 26, 2026 /PRNewswire/ — Pinnacle Medicines (“Pinnacle” or “The Company”), a biotechnology company leading the development of oral peptide therapeutics using proprietary AI and physics-based platforms, today announced the closing of an $89 million Series B funding round. The round was co-led by LAV and Foresite Capital, with participation from existing investors including Quan Capital, Hong Kong Capital, RA Capital Management, Logos Capital and OrbiMed.
Proceeds from the financing will help advance Pinnacle’s pioneering programs through clinical proof-of-concept, with an initial focus on immunology and cardiometabolic diseases, while further expanding the company’s proprietary peptide discovery platform and research and development capabilities. Pinnacle Medicines is developing a new generation of oral peptide drugs designed to deliver biologic-level safety and efficacy with the convenience of oral dosing.
“This funding marks an important milestone for Pinnacle Medicines and reflects our strong belief in the transformation of oral peptide therapies,” said Jonathan Wang, Chief Executive Officer of Pinnacle Medicines. “At Pinnacle, we are building a platform designed to unlock the full therapeutic potential of peptides through oral delivery. With this strong group of investors, we are now focused on translating this vision into clinical proof and delivering transformative medicine to patients.”
Chengzhao Sun, Ph.D., Chief Scientific Officer and Co-Founder, added: “We have assembled an experienced peptide drug discovery and development team across key disciplines and developed a proprietary platform that integrates AI technology with physics-based simulations to rationally design and reflect the rapid development of our pipeline strengths. This approach positions us to develop a new generation of oral peptide drugs for chronic diseases.”
“We are very excited about the future of oral peptide therapy, and Pinnacle Medicine is emerging as a leader in this area,” said Cindy Zheng, partner at Forsyth Capital. “The team brings deep experience in peptide drug development and a demonstrated ability to rapidly develop both a differentiated discovery platform and a promising first-in-class pipeline. We look forward to supporting the company as it accelerates these programs toward clinical development.”
David Wang, MD, Ph.D. Partner and Senior Managing Director at OrbiMed, added: “We have supported Pinnacle Medicines since its inception and have been impressed by the team’s scientific vision and execution. Oral peptide medicines have the potential to transform treatment paradigms in many disease areas, and we continue to support this project as the company’s pipeline progresses. The concept.”
About panic medication
Pinnacle Medicines is a biotechnology company focused on developing a new generation of oral peptide therapies designed to deliver biologic-level efficacy with the convenience of oral dosing. The company is developing a differentiated discovery platform that integrates physics-based molecular simulations, artificial intelligence-enabled design, and advanced peptide chemistry to rationally design and optimize peptide drugs. Pinnacle is developing a pipeline of potentially first and best-in-class oral peptide programs that target pathways believed to be involved in immune and cardiometabolic diseases.
For more information, please visit www.pinnaclemedicines.com.
About the LAV
LAV is a global biomedical investment company with offices in Hong Kong, Shanghai and Palo Alto. Started in 2008 as a subsidiary of Eli Lilly Corporate, we evolved into an independent investment management company in 2011. Our team of more than 50 professionals with experience in science, medicine, investment, and operations embraces a culture of integrity, teamwork, passion, and science.
For more information, please visit www.lavfund.com.
About Foresite Capital
Foresite Capital is a multi-stage healthcare, science and technology investment firm with over $3 billion in assets under management. The company targets areas of great unmet need by funding promising businesses at all stages of their life cycle. Founded in 2011, Foresite Capital has locations in the San Francisco Bay Area, Los Angeles, and New York City.
For more information, please visit www.foresitecapital.com.
About OrbiMed
OrbiMed is a leading healthcare investment firm, with $19 billion in assets under management. OrbiMed invests in the healthcare industry worldwide, from start-ups to large multinational corporations, through private equity funds, public equity funds, and discretionary/credit funds. OrbiMed strives to be the capital provider of choice, providing tailored financing solutions and extensive global group resources to help build world-class healthcare companies. OrbiMed’s team of more than 130 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
For more information, please visit www.orbimed.com.
Corporate communication
Yuu Chen
Cotton medicine
[email protected]
215.267.8029
Media Relations
David Scholl or Ignacio Guerrero-Ross, Ph.D.
Friends of Russia
[email protected]
[email protected]
858.717.2310
Source Pinkel Medicine
#Pinnacle #Medicines #pioneer #oral #peptide #therapeutics #announced #additional #million #Series #funding #advance #pipeline #clinical #trials